Did Elon Musk really leave the US over Alzheimer drugs?

1. What the evidence actually shows about Musk and Alzheimer’s

Reporting in the set links Musk to interest in neurological disease chiefly through his company Neuralink, which the CEO says will scale production of brain‑computer interface devices and aims to help people with severe neurological conditions including Alzheimer’s and Parkinson’s, and has moved into human trials—coverage that frames Musk as an actor in potential therapies rather than someone abandoning the country over them ^{[2] [4] [5]}. Independent coverage also shows Musk reacting publicly to Alzheimer’s‑related science and lifestyle studies—such as those linking sleep to dementia risk—but none of the supplied items claims he left the United States because of a drug approval or policy decision ^{[1] [5]}.

2. Where the rumor could plausibly come from — conflation of different threads

A plausible source of confusion is the collision of three separate narratives in the public record: high‑profile drug developments (for example the drug lecanemab’s promising trial data and approvals reported in mainstream outlets), Musk’s vocal obsession with neuroscience technologies, and his habit of volatile political moves and public theatrics; combining those can create a narrative that he reacted dramatically by leaving the country, but the supplied coverage shows only policy‑and‑media activity, not an exit ^{[6] [2] [3]}. Opinion pieces and polemical posts that cast Musk as a destructive force in public science funding may amplify fears about his influence on Alzheimer’s research, but amplification is not the same as evidence of relocation ^{[7] [3]}.

3. What about the claim that Alzheimer drugs are being withheld or politicized?

The sources document debate and excitement around Alzheimer’s therapies—such as lecanemab slowing disease progression in trials—and concern about access and the wider implications of research funding, but they do not document a causal chain in which a billionaire’s personal migration is a response to drug approvals or denials ^[6]. Some comment and advocacy pieces argue that shifts in funding and the public/private balance affect research ecosystems; Broke‑Ass Stuart’s commentary frames private actors like Musk as reshaping academic incentives, but that is an opinion piece, not evidence Musk left the country over a drug dispute ^[7].

4. Alternative interpretations and hidden agendas in the coverage

Different outlets carry different explicit agendas: opinion columns use Musk as a convenient focal point for critiques of privatization and political influence ^{[3] [7]}, science outlets emphasize the technical aspects of transmission risks and biotech advances ^{[5] [8]}, and business coverage highlights Neuralink’s commercialization plans ^[2]. Where conspiratorial narratives tie Musk’s actions to apocalyptic outcomes for Alzheimer’s research, the supplied sources either critique his broader political influence or report on his companies’ ambitions—neither constitutes documentation of him emigrating over a drug issue ^{[3] [2] [7]}.

5. Bottom line and reporting limitations

Based on the provided material, the direct answer is: no, he did not “really leave the US over Alzheimer drugs” as far as these sources reveal; they show Musk active in US‑based ventures, politics and public commentary, and pursuing Neuralink’s medical agenda domestically ^{[2] [3] [1]}. If there is reporting elsewhere that he physically left the United States for reasons tied to Alzheimer’s therapies, that evidence is not present in the supplied documents and cannot be corroborated here (limitation acknowledged).